Abstract The invention concerns a composition, i.e., a multifunctional medically active agent for rational therapy of malignant (cancerous) diseases based on cause-and-effect relationship. The new composition according to the invention contains dimethylsulfoxide, DMSO, or sulfolan, preferably DMSO, in combination with a therapeutically effective amount of at least one cytostatic agent. The invention also concerns a method for treatment of malignant (cancerous) conditions in man comprising local or systemic administration thereto of an effective dosage of the composition according to the invention. The invention surprisingly provides a composition, as well as a method of treatment, allowing rational specific or selective carcinostatic-carcinocidic therapy. This therapy-form aims at the intracytoplasmic 3-dimensional cytoskeleton (differentiation organelle) that is specifically changed in the malignant cells, as well as at the targets responsible for karyokinesis and cytokinesis.
A method of treatment of skin cancer in man comprising percutaneous or intravenous administration thereto of an effective dosage of a composition comprising in combination dimethylsulfoxide and a therepeutically effective subthreshold dose of a cytostatic agent selected from the group consisting of colchicine, vinblastine sulfate, phloridzin, triethylene thiophosphamide, cyclophosphamide, humic acid, fluorouracil and mechlorethamine.
Claim 2
Independent Claim
54 words
A method of treatment of skin cancer in man comprising percutaneous or intravenous administration thereto of an effective dosage of a composition comprising in combination dimethylsulfoxide and a therepeutically effective subthreshold dose of a cytostatic agent selected from the group consisting of colchicine, vinblastine sulfate, phloridzin, triethylene thiophosphamide, cyclophosphamide, humic acid, fluorouracil and mechlorethamine.
Claim 3
Dependent Claim
19 words
The method of claim 1 wherein vinblastine sulfate is used in a dosage of 0.001-0.05 mg/week/kg body weight i.v.
Claim 4
Dependent Claim
19 words
The method of claim 1 wherein fluorouracil is used in an initial dosage of 0.12-1.2 mg/day/kg body weight i.v.
Claim 5
Dependent Claim
18 words
The method of claim 1 wherein cyclophosphamide is used in a dosage of 0.1-2.0 mg/day/kg body weight i.v.
Claim 6
Dependent Claim
18 words
The method of claim 1 wherein mechlorethamine is used in a dosage of 0.004-0.04 mg/kg body weight i.v.